FMR LLC reports 11.1% stake in Nektar Therapeutics
Nektar Therapeutics reports that FMR LLC beneficially owns 3,036,760.61 shares of common stock, representing 11.1% of the class as reported on 02/27/2026.
Nektar Therapeutics reports that FMR LLC beneficially owns 3,036,760.61 shares of common stock, representing 11.1% of the class as reported on 02/27/2026. The filing is a Schedule 13G disclosing ownership and states Abigail P. Johnson holds dispositive power over the same 3,036,760.61 shares. The filing references an agreement in Exhibit 99 and is signed by an authorized representative of FMR LLC.
Positive
None.
Negative
None.
Insights
Large passive stake disclosed by FMR LLC: 3,036,760.61 shares (11.1%).
FMR LLC reports beneficial ownership of 3,036,760.61 shares, equal to 11.1% of Nektar Therapeutics' common stock as of 02/27/2026. The Schedule 13G framing typically indicates passive investment intent rather than an active solicitation of control.
Key dependencies include whether the position remains passive under Rule 13d-1; Exhibit 99 is cited for a 13d-1(k) agreement. Subsequent filings would clarify any change in voting or transaction plans.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake does FMR LLC report in NKTR?
FMR LLC reports beneficially owning 3,036,760.61 shares, representing 11.1% of NKTR common stock as of 02/27/2026. The amount and percentage appear on the Schedule 13G cover and Item 4 ownership section.
Does Abigail P. Johnson have voting or dispositive power over NKTR shares?
Abigail P. Johnson is reported with sole dispositive power over 3,036,760.61 shares. The filing shows 0.00 shared voting power and lists her dispositive authority in Item 4.
What form was filed to report FMR LLC's NKTR holdings?
A Schedule 13G was filed to report the position. The cover lists the issuer as Nektar Therapeutics and the filing discloses ownership details and an Exhibit 99 reference.
Is the filing indicative of an activist intent by FMR LLC?
The Schedule 13G format generally indicates a passive position rather than activist intent. The filing does not state any solicitation, and Exhibit 99 is cited for a 13d-1(k) agreement.
Where can I find more details about the ownership agreement referenced?
The filing references Exhibit 99 for a 13d-1(k) agreement. Exhibit 99 should contain the agreement text and any conditions governing the reported ownership and powers.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
NEKTAR THERAPEUTICS
(Name of Issuer)
COMMON STOCK
(Title of Class of Securities)
02/27/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
SCHEDULE 13G
CUSIP Number(s):
1
Names of Reporting Persons
FMR LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
3,032,178.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
3,036,760.61
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,036,760.61
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
11.1 %
12
Type of Reporting Person (See Instructions)
HC
SCHEDULE 13G
CUSIP Number(s):
1
Names of Reporting Persons
Abigail P. Johnson
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
3,036,760.61
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,036,760.61
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
11.1 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
NEKTAR THERAPEUTICS
(b)
Address of issuer's principal executive offices:
455 MISSION BAY BOULEVARD SOUTH,SAN FRANCISCO,CA,US,94158
Item 2.
(a)
Name of person filing:
FMR LLC
(b)
Address or principal business office or, if none, residence:
245 Summer Street, Boston, Massachusetts 02210
(c)
Citizenship:
Not applicable
(d)
Title of class of securities:
COMMON STOCK
(e)
CUSIP No.:
640268306
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
3036760.61
(b)
Percent of class:
11.1 %
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
Please see the responses to Items 5 and 6 on the cover page.
(ii) Shared power to vote or to direct the vote:
0.00
(iii) Sole power to dispose or to direct the disposition of:
3036760.61
(iv) Shared power to dispose or to direct the disposition of:
0.00
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of NEKTAR THERAPEUTICS. No one other person's interest in the COMMON STOCK of NEKTAR THERAPEUTICS is more than five percent of the total outstanding COMMON STOCK.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
See attached Exhibit 99.
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
FMR LLC
Signature:
Stephanie J. Brown
Name/Title:
Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries*
Date:
03/05/2026
Abigail P. Johnson
Signature:
Stephanie J. Brown
Name/Title:
Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson**
Date:
03/05/2026
Comments accompanying signature: * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.
